4820 Richard Road SW
Suite 300
Calgary, AB T3E 6L1
Canada
403 254 9252
http://www.resverlogix.com
Sector(s):Â Healthcare
Industry:Â Biotechnology
Full Time Employees:Â 25
Name | Title | Pay | Exercised | Year Born |
---|---|---|---|---|
Mr. Donald J. McCaffrey | Co-Founder, Chairman, Pres, CEO & Sec. | 505.2k | N/A | N/A |
Mr. Aaron Bradley Cann C.A., CPA, CA, CPA, CBV | Chief Financial Officer | 281.8k | N/A | N/A |
Mr. Kenneth Eugene Lebioda BA | Sr. VP of Bus. & Corp. Devel. | 264.6k | N/A | N/A |
Dr. Michael Sweeney | Sr. VP of Clinical Devel. | 525.29k | N/A | 1961 |
Dr. Ewelina Kulikowski | Sr. VP of R&D | 250k | N/A | N/A |
Dr. Norman C.W. Wong B.Sc., FRCPC, M.Sc., B.Sc (Hon), M.Sc, M.D., FRCP( | Co-Founder, Chief Scientific Officer & Chairman of the Scientific Advisory Board | N/A | N/A | N/A |
Mr. Paul Moon | VP of Investor Relations & Communications | N/A | N/A | N/A |
Sarah Zapotichny | Director of Investor Relations & Corp. Communications | N/A | N/A | N/A |
Dr. Jan O. Johansson | Sr. VP of Medical Affairs | N/A | N/A | N/A |
Resverlogix Corp. operates as a late-stage clinical biotechnology company. The company is developing apabetalone (RVX-208), a small molecule selective bromodomain and extra-terminal inhibitor that is in Phase III clinical trials for patients with cardiovascular, chronic kidney, end-stage renal, neurodegenerative, fabry, peripheral artery, and other orphan diseases, as well as diabetes mellitus. Resverlogix Corp. is headquartered in Calgary, Canada.
Resverlogix Corp.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.